Viral IL-10 gene therapy inhibits TNF-α and IL-1β, not IL-6, in the newborn endotoxemic mouse☆,☆☆
References (21)
- et al.
Interleukin 1 and tumor necrosis factor production as the initial stimulants of liver ischemia and reperfusion injury
J Surg Res
(1994) - et al.
Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid
Lancet
(1985) - et al.
Interleukin-10 production during septicaemia
Lancet
(1994) - et al.
Modified immunological status of anti-IL-10 treated mice
Cell Immunol
(1993) - et al.
Interleukin-6 elevation in critically ill infants with sepsis and necrotizing enterocolitis
J Pediatr
(1994) - et al.
Adenoviral transduction of liver allografts achieves regional levels of viral IL-10 which suppress alloreactivity in vitro
J Surg Res
(1995) - et al.
Inhibition of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta) secretion but not IL-6 from activated human peripheral blood monocytes by a new synthetic demethylpodophyllotoxin derivative
J Clin Immunol
(1994) - et al.
Plasma cytokine levels in necrotizing enterocolitis
Acta Paediatr
(1994) - et al.
Neonatal tumor necrosis factor, interleukin-1 alpha, interleukin-1 beta, and interleukin-6 response to infection
Am J Perinatol
(1994) - et al.
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin
Science
(1985)
Cited by (39)
Interleukin-10 deficiency aggravates angiotensin II-induced cardiac remodeling in mice
2016, Life SciencesCitation Excerpt :Moreover, proinflammatory cytokines are known to induce apoptosis, collagen production, matrix metalloproteinase (MMP) activation, fibrosis, and ventricular dilation, which leads to heart failure [1,3]. IL-10 is a potent anti-inflammatory cytokine that inhibits the lipopolysaccharide-induced production of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 [4,5]. IL-10 also acts as an antioxidant and inhibits the generation of reactive oxygen species (ROS) by TNF-α in cardiac myocytes [6].
Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1β transgenic mice subjected to the lipopolysaccharide-induced sepsis
2015, BiomaterialsCitation Excerpt :Like TNF-α, IL-1β is an alarm-phase cytokine that can elicit numerous clinical features of sepsis. IL-10 is an important anti-inflammatory and immune inhibitory cytokine secreted by macrophages, which inhibits TNF-α and increases the IL-1 receptor antagonist [56–58]. These studies suggested that inhibition of IL-6, TNF-α, and IL-1β or promotion of IL-10 tended to alleviate LPS-induced sepsis.
Novel bisabolane derivative from "arnica-da-serra" (Vernonieae: Asteraceae) reduces pro-nociceptive cytokines levels in LPS-stimulated rat macrophages
2013, Journal of EthnopharmacologyCitation Excerpt :Nevertheless, some studies have demonstrated that IL-1β and TNF can play a role in an inflammatory cascade without the participation of IL-6 (Cunha et al., 2005). Similar results in cell cultures were found by Drazan et al. (1996) where the TNF-alpha and IL-1 beta, but not IL-6 are suppressed in Kupffer cell response to LPS. The treatment with the orto-acetoxy-bisabolol did not induce any change on the nitric oxide (NO) levels induced by LPS on the culture supernants.
Immunosuppressive effect on T cell activation by interleukin-16- and interleukin-10-cDNA-double-transfected human squamous cell line
2009, BurnsCitation Excerpt :IL-10 also strongly reduces antigen-specific T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of MHC class II expression [31]. Because IL-10 is well known as an immunosuppressive cytokine, attempts have been made to more thoroughly investigate its function in a number of in vivo models including endotoxemia [32–36], transplantation [37–39], autoimmune diseases [40], diabetes in non-obese mice [41] and allergen-induced lung inflammation [42]. In this study, we demonstrated that IL-16 enhanced or added independently to the immunosuppressive effect of IL-10 in allogeneic MLR.
The Cytokine Basis of Cachexia and its Treatment: Are They Ready for Prime Time?
2008, Journal of the American Medical Directors AssociationCitation Excerpt :Fujiki and Mukaida271 used IL-10 gene transfer in the cachexia mouse model (animals with an adenocarcinoma) and found that this can increase serum IL-10 levels, thereby decreasing IL-6 levels and retarding further weight loss and hypophagia. Drazan et al272 also found that IL-10 gene therapy using viral vectors can inhibit TNF-α and IL-1β production, thus preventing endotoxemic sepsis in mice. PGE2 can augment but not induce IL-6 and IL-10 secretion.
- ☆
Presented in part at the 26th Annual Meeting of the American Pediatric Surgical Association, Boca Raton, Florida, May 1995.
- ☆☆
Supported by the Ethicon-Society of University Surgeons Research Award (K.E.D.) and National Institutes of Health Grant No. DK43111 (A.S.).